Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HDAC6/MAO-A/LSD1 Inhibitor
HDAC6-IN-3 is a potent inhibitor of histone deacetylase 6 (HDAC6), with an IC50 ranging from 0.02 to 1.54 μM for various HDAC isoforms, including HDAC1, HDAC2, HDAC3, and HDAC8. Additionally, it exhibits significant inhibitory activity against monoamine oxidase A (MAO-A) with an IC50 of 0.79 μM and lysine-specific demethylase 1 (LSD1). This compound serves as a valuable tool for research applications in cancer biology and epigenetics and is equipped with an alkyne functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
EZH2/HSP90 Inhibitor
EZH2/HSP90-IN-29 is a dual inhibitor targeting both EZH2 and HSP90, exhibiting IC50 values of 6.29 nM for EZH2 and 60.1 nM for HSP90. This compound enhances the expression of apoptosis and necrosis-related genes, induces M-phase cell cycle arrest, and disrupts the reactive oxygen species catabolism pathway. Additionally, EZH2/HSP90-IN-29 has the capability to cross the blood-brain barrier, making it a valuable tool for research in cancer biology and neurodegenerative diseases. -
Ferroptosis Inhibitor
1(R)-(Trifluoromethyl)oleyl alcohol is a trifluoromethyl alcohol derivative of oleic acid that functions as a ferroptosis inhibitor. This compound effectively attenuates ferroptosis induced by Erastin and mitigates lipid peroxidation in human myoblasts with frataxin (FXN) siRNA knockdown. At a concentration of 40 μM, it enhances cell survival to 95% in models of Friedreich ataxia where cell death is largely driven by iron accumulation and glutathione depletion. This makes 1(R)-(Trifluoromethyl)oleyl alcohol a valuable reagent for studying ferroptosis and its related pathways in neurodegenerative diseases. -
Ferroptosis Inhibitor
Ferroptosis-IN-3 is a potent ferroptosis inhibitor targeting the ferroptotic cell death pathway. It effectively inhibits RSL3-induced ferroptosis in HT-1080 cells with an EC50 of 8.6 nM. Additionally, Ferroptosis-IN-3 demonstrates strong free radical scavenging properties, with EC50 values of 3.94 μM for DPPH and 6.3 μM for ABTS, and reduces lipid peroxidation. This compound is ideal for research focused on oxidative stress and cell death mechanisms. -
15LOX-2 Inhibitor
FerroLOXIN-1 is a potent inhibitor of the enzyme 15-lipoxygenase-2 (15LOX-2) that effectively reduces the production of pro-ferroptotic lipid species, specifically HOO-ETE-PE. This compound has demonstrated protective effects against RSL3-induced ferroptosis, making it a valuable tool in studying ferroptotic pathways. The selective interaction of FerroLOXIN-1 with the active site residues Y154, N155, and W158 of 15LOX-2 underscores its targeted mechanism of action, positioning it as a valuable reagent for research into lipid metabolism and ferroptosis. -
Ferroptosis Inhibitor
Ferroptosis Inducer-6 is a potent inducer of ferroptosis, primarily functioning through the generation of reactive oxygen species (ROS) and the induction of oxidative stress and mitochondrial damage. This compound exhibits anti-tumor activity and serves as a valuable tool for research in type I and II photodynamic therapy. Its ability to trigger ferroptotic cell death makes it significant for studies focused on cancer treatment and exploring the mechanisms of cell death pathways. -
TrxR1 Inhibitor
CS47 is a reversible inhibitor of Thioredoxin reductase 1 (TrxR1). It activates stress-responsive pathways involving glutathione (GSH) and iron regulation, leading to GSH depletion, heightened heme oxygenase-1 (HO-1) expression, and intracellular iron overload, ultimately inducing ferroptosis in KRAS-independent lung cancer models. CS47 demonstrates significant anticancer activity while exhibiting low cytotoxicity towards normal lung fibroblasts, making it a valuable tool for studying cancer mechanisms and therapeutic strategies. -
Ferroptosis Inhibitor
Ferroptosis-IN-11 is a potent ferroptosis inhibitor targeting the pathways involved in iron-mediated cell death. It effectively inhibits Erastin-induced ferroptosis in HT-1080 human fibroblasts, demonstrating an EC50 of 36 nM. This compound is valuable for research into cardiovascular diseases and neurodegenerative disorders, providing insights into the mechanisms of ferroptosis and potential therapeutic strategies. -
Ferroptosis/MAO-B Inhibitor
MAO-B-IN-45 is a selective inhibitor of MAO-B with an IC50 of 87.47 nM, demonstrating over 229-fold selectivity for MAO-B compared to MAO-A. This compound exhibits significant antiferroptosis activity by modulating the iron metabolic pathway and the glutathione peroxidase 4 (GPX4) axis in vitro. Research indicates that MAO-B-IN-45 enhances cognitive and behavioral functions in 3×Tg (APP/Tau/Ps1) Alzheimer's disease mouse models, while also reducing levels of ferritin heavy chain 1 (FTH1), amyloid precursor protein (APP), and phosphorylated Tau (p-Tau) in the brain. -
Ferroptosis Inhibitor
Ferrostatin-1 diyne is a potent ferroptosis inhibitor that selectively targets the ferroptotic pathway. This compound is known to accumulate in lysosomes, mitochondria, and the endoplasmic reticulum of cells. Notably, its inhibition of ferroptosis occurs independently of lysosomal and mitochondrial activity, making it a valuable tool for studying ferroptosis-related mechanisms and evaluating therapeutic strategies in various research applications. -
Ferroptosis Inhibitor
RC574 is a novel ferroptosis inhibitor that protects mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death. It enhances levels and activity of glutathione peroxidase 1 (GPx1), vital for cellular antioxidant defense. This compound is valuable for research into neuroprotection and the mechanisms underlying ferroptosis in neurodegenerative diseases. -
HMG-CoA Reductase Inhibitor
Cerivastatin is a highly potent HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. This synthetic lipid-lowering agent effectively reduces low-density lipoprotein cholesterol levels. In addition to its lipid-modulating effects, Cerivastatin has exhibited inhibitory effects on the proliferation and invasiveness of MDA-MB-231 breast cancer cells, primarily through the inhibition of RhoA signaling, indicating potential applications in cancer research. -
TrxR/EGFR Inhibitor
TrxR/EGFR-IN-1 is a potent inhibitor targeting both Thioredoxin Reductase (TrxR) and Epidermal Growth Factor Receptor (EGFR). This compound demonstrates significant anti-proliferative effects against Gefitinib-sensitive and resistant lung cancer cells, facilitating apoptosis and tumor cell death. TrxR/EGFR-IN-1 promotes GPX4 protein degradation via autophagolysosomal and proteasomal pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it a valuable tool for studying mechanisms underlying Gefitinib-resistant lung cancer. -
Ferroptosis Inhibitor
Ferroptosis-IN-4 is a potent ferroptosis inhibitor, exhibiting an EC50 value of 20 μM. This compound demonstrates minimal cytotoxicity, highlighting its safety for biological applications. Ferroptosis-IN-4 provides a protective effect in models of glycerol-induced renal acute kidney injury (RM-AKI), effectively alleviating kidney dysfunction. Its ability to modulate ferroptosis makes it a valuable tool for research in cellular stress responses and kidney-related disorders. -
Ferroptosis Inhibitor
5-Hydroxy-6,7-dimethoxyflavone is a potent inhibitor of ferroptosis, acting primarily to mitigate H1N1 virus-induced cell death. This compound enhances the expression of SLC7A11 and GPX4, thereby providing protective effects against ferroptosis. Additionally, it reduces inflammatory responses and apoptosis by inhibiting the activation of NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone is valuable for research related to H1N1 influenza virus infection and ferroptosis regulation. -
Ferroptosis inhibitor
3-Hydroxyindole is a hydroxyindole derivative known for its potent antioxidant activity. It exhibits inhibitory effects against DPPH and crocin, making it a valuable tool in studies of oxidative stress. Additionally, 3-hydroxyindole is recognized for its role as a ferroptosis inhibitor, facilitating research into this regulated form of cell death and its implications in various diseases. -
Ferroptosis Inhibitor
Ferroptosis-IN-5 is a potent ferroptosis inhibitor that functions by chelating iron and scavenging reactive oxygen species (ROS). This compound effectively mitigates ferroptotic cell death, making it valuable for research in cancer biology and neurodegeneration. Applications include investigating the mechanisms of ferroptosis and evaluating potential therapeutic interventions in various diseases associated with oxidative stress. -
Ferroptosis Inhibitor
Ferfluor-1 is a potent ferroptosis inhibitor, demonstrating EC50 values of 57 nM in HT108 cells, 75 nM in OS-RC-2 cells, and 2.3 nM in SH-SY5Y neuroblastoma cells. This ratiometric photoluminescent probe is capable of crossing the blood-brain barrier, making it an effective tool for monitoring ferroptotic changes in cellular environments. Ferfluor-1 shows promise in research applications related to neurodegenerative diseases, such as stroke and Parkinson's disease, by mitigating the effects of ferroptosis in in vivo models. -
Ferroptosis Inhibitor
Ferroptosis-IN-15 is a potent ferroptosis inhibitor, exhibiting EC50 values of 0.76 μM in A375 cells and 0.67 μM in 786-O cells. This compound functions as a potential iron chelator and radical trapping antioxidant, making it a valuable tool for studying the mechanisms of ferroptosis. Its ability to modulate ferroptotic cell death contributes to research in cancer biology and neurodegenerative disorders. -
Ferroptosis Inhibitor
Ferroptosis-IN-18 is a potent ferroptosis inhibitor that exhibits significant anti-ferroptotic and antioxidant properties. This compound is particularly relevant in research focused on intracerebral hemorrhage (ICH), providing valuable insights into the mechanisms of ferroptosis and potential therapeutic approaches. Its ability to modulate ferroptosis-related pathways makes it a valuable tool in the understanding of oxidative stress-related conditions. -
Ferroptosis inhibitor
Myosin-IN-3 is a pyrimidine ketone derivative that functions as a ferroptosis inhibitor. Demonstrating potent anti-ferroptotic activity with an IC50 of 3.11 μM, it also effectively inhibits myosin activity (IC50 = 3.09 μM) and exhibits antioxidant properties, as evidenced by DPPH (EC50 = 23.17 μM) and MDA (EC50 = 55.34 μM) assays. Myosin-IN-3 is applicable in research related to cardiovascular diseases, including hypertrophic cardiomyopathy. -
Ferroptosis Inhibitor
Ferroptosis-IN-6 is a potent ferroptosis inhibitor with an EC50 of 25.5 nM. This compound effectively inhibits RSL3-induced cell death both in vitro and in vivo, making it a valuable tool for studying ferroptosis mechanisms. Its applications include investigating cell death pathways and potential therapeutic strategies in cancer and neurodegenerative diseases. -
Ferroptosis Inhibitor
CuATSP is a potent inhibitor of ferroptotic cell death, demonstrating approximately 20-fold greater efficacy compared to its predecessor, CuATSM. This compound has significant implications for research focused on cell death mechanisms and oxidative stress-related diseases. It is valuable for studying the pathways involved in ferroptosis and its potential therapeutic applications in various conditions, including neurodegenerative disorders and cancer. -
15-Lipoxygenase Inhibitor
Utreloxastat (PTC857) is a selective inhibitor of 15-lipoxygenase, capable of crossing the blood-brain barrier. This compound demonstrates a significant ability to reduce oxidative stress, inhibit the depletion of reduced glutathione, and prevent ferroptosis. Utreloxastat is particularly relevant in the research of neurodegenerative diseases associated with elevated oxidative stress and mitochondrial dysfunction, including conditions such as amyotrophic lateral sclerosis. -
Ferroptosis/NETosis Inhibitor
IM-93 is a potent inhibitor of ferroptosis and NETosis, with an IC50 of 0.45 µM for the inhibition of cell death. This compound serves as a valuable tool for researchers investigating the mechanisms of ferroptosis and NETosis in various biological contexts. Its ability to modulate these cell death pathways can aid in the exploration of therapeutic strategies for diseases associated with oxidative stress and inflammation. -
Ferroptosis Inhibitor
Ferroptosis-IN-19 is a potent ferroptosis inhibitor exhibiting an IC50 value of 0.097 μM. This compound demonstrates high metabolic stability and favorable predictions for blood-brain barrier permeation. Ferroptosis-IN-19 has been shown to provide neuroprotective effects in vivo against ischemic brain injury in murine models, making it a valuable tool for exploring ferroptosis in neurological research. -
Ferroptosis Inhibitor
Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. This compound effectively lowers lipid reactive oxygen species (ROS) levels in cellular systems. By acting as an antioxidant that captures lipid radicals, Ferroptosis-IN-8 mitigates the accumulation of detrimental lipid peroxides, thereby inhibiting the ferroptotic process. This reagent is valuable for research in cell death mechanisms and oxidative stress. -
Ferroptosis Inhibitor
Ferroptosis-IN-21 is a selective ferroptosis inhibitor that mitigates renal ischemia/reperfusion (I/R) injury by suppressing ferroptosis and effectively scavenging peroxyl radicals. Demonstrating nanomolar potency, it exhibits significant anti-ferroptotic activity in renal tubular epithelial cells, leading to a marked reduction in lipid reactive oxygen species (ROS) and lipid peroxidation biomarkers such as 4-hydroxynonenal. In preclinical studies, Ferroptosis-IN-21 has shown to alleviate histological damage and functional impairment in mice models of renal I/R injury, making it a valuable reagent for research in ferroptosis-targeted therapeutic development. -
Ferroptosis Inhibitor
Ferroptosis-IN-22 is a selective ferroptosis inhibitor that targets and disrupts the interaction between NCOA4 and ferritin, demonstrating an EC50 of 520 nM and a Kd of 0.78 μM. This compound exhibits potent inhibitory activity against ferroptosis induced by agents such as RSL3, Erastin, ML210, and FIN56, while sparing necrosis and apoptosis pathways. Ferroptosis-IN-22 has shown efficacy in ameliorating acute liver injury induced by Concanavalin A, making it a valuable tool for research in ferroptosis-related diseases. -
xc(-) Cystine/Glutamate Transporter System Inhibitor, ferroptosis inducer
Erastin2 is a selective inhibitor of the xc(-) cystine/glutamate transporter, functioning as a potent inducer of ferroptosis. This compound disrupts intracellular cystine availability, leading to increased oxidative stress and subsequent cell death. Erastin2 is valuable for research applications targeting ferroptosis in cancer biology and neurodegenerative diseases, providing insights into therapeutic strategies that exploit this regulated cell death pathway. -
Ferroptosis inhibitor
Trans-3-Indoleacrylic acid is a ferroptosis inhibitor that acts through modulation of the AHR-ALDH1A3-FSP1-CoQ10 axis. It has been shown to promote tumor development by inhibiting RSL3-induced ferroptosis, thereby contributing to the progression of colorectal carcinogenesis. This compound serves as a valuable tool for research into ferroptosis mechanisms and cancer biology. -
HMG-CoA Reductase Inhibitor
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. -
Ferroptosis Inhibitor
84-B10 is a potent ferroptosis inhibitor derived from 3-phenylglutaric acid. It effectively inhibits cisplatin-induced tubular ferroptosis, thereby mitigating mitochondrial damage and oxidative stress associated with cisplatin treatment. Consequently, 84-B10 demonstrates protective effects against cisplatin-induced acute kidney injury (AKI), making it a valuable reagent for research on drug-induced nephrotoxicity and ferroptosis-related mechanisms. -
ZIKV And EBOV Inhibitor, Histone H3 Acetylation Inductor, Ferroptosis Inductor
Cephaeline is a phenolic alkaloid derived from the roots of Cephaelis ipecacuanha, functioning as a potent inhibitor of Zika virus (ZIKV) and Ebola virus (EBOV) infections. It induces histone H3 acetylation, playing a role in epigenetic regulation, and has been shown to induce ferroptosis in mucoepidermoid carcinoma cancer stem cells by inhibiting NRF2. This makes Cephaeline a valuable reagent for researchers studying antiviral mechanisms and ferroptosis in cancer therapy. -
Ferroptosis Inhibitor
Liproxstatin-1 hydrochloride is a potent inhibitor of ferroptosis, a regulated form of cell death characterized by lipid peroxidation. It effectively prevents ferroptotic cell death with an IC50 value of 22 nM. This compound is valuable for research applications focused on oxidative stress, neurodegenerative diseases, and cancer, where modulating ferroptosis may provide therapeutic insights. -
Ferroptosis Inhibitor
YL-939 is a potent inhibitor of ferroptosis, a regulated form of cell death characterized by the accumulation of lipid peroxides. It acts by targeting the PHB2/ferritin/iron axis, effectively modulating iron metabolism and oxidative stress. This compound is valuable for research applications focused on neurodegeneration, cancer, and other diseases where ferroptosis plays a critical role. -
Ferroptosis Inhibitor
CuATSM is a copper complex that serves as a potent inhibitor of ferroptosis through the scavenging of free radicals and inhibition of lipid peroxidation. This compound demonstrates significant antioxidant and anti-inflammatory properties, making it valuable for addressing neuroprotection in various research contexts. CuATSM is suitable for studies exploring cellular stress responses and neurodegenerative disorders. -
Ferroptosis/ATF3 Inhibitor
ATF3-IN-1 is a potent inhibitor of ATF3, targeting the ATF3/SLC7A11/GPX4 pathway to mitigate ferroptosis and oxidative stress. This compound demonstrates significant neuroprotective effects, particularly in conditions of ischemia/reperfusion (I/R) injury, promoting neuronal survival in ischemic stroke models. ATF3-IN-1 is valuable for research into therapeutic strategies for neuroprotection and the underlying mechanisms of ischemic stroke. -
Ferroptosis Inhibitor
Moracin N is a potent ferroptosis inhibitor derived from mulberry leaves. It demonstrates neuroprotective activity by mitigating oxidative stress, providing valuable insights into the mechanisms of cell survival under stress conditions. This compound is applicable in research exploring neurodegenerative diseases and ferroptosis-related pathways. -
Endogenous Metabolite; Nrf2 Activator; ROS Inhibitor
L-Cystine hydrochloride is an endogenous metabolite that serves as a potent Nrf2 activator and reactive oxygen species (ROS) inhibitor. It enhances Nrf2 protein expression, facilitating transcriptional responses that combat oxidative stress. Research indicates that L-Cystine hydrochloride reduces ROS generation and protects cells from apoptosis induced by oxidants or Doxorubicin. Additionally, its combination with L-theanine has been shown to boost antigen-specific IgG production by elevating glutathione levels and promoting T helper 2 (Th2) responses. This compound has significant potential for studying cystinuria and kidney stone formation. -
Ferroptosis Inhibitor
SRS16-86 is a potent ferroptosis inhibitor that provides enhanced stability in vivo compared to other inhibitors. This compound is effective in research applications involving renal ischemia-reperfusion injury and spinal cord injury, making it a valuable tool for investigating ferroptosis-related pathways and therapeutic interventions. SRS16-86 allows researchers to explore the mechanisms of ferroptosis and its implications in various diseases. -
Carbonic Anhydrase Inhibitor
Zonisamide is an orally active inhibitor of carbonic anhydrases, demonstrating Ki values of 35.2 nM for human carbonic anhydrase II and 20.6 nM for human carbonic anhydrase V. This compound exhibits neuroprotective properties by promoting anti-apoptotic mechanisms and enhancing manganese superoxide dismutase (MnSOD) expression. Additionally, Zonisamide has been shown to upregulate Hrd1 expression, which contributes to improved cardiac function in animal models of cardiac hypertrophy. Research applications include investigations into seizures, Parkinson's disease, and cardiac hypertrophy. -
PDEIII Inhibitor
Anagrelide hydrochloride is a selective phosphodiesterase type III (PDE3) inhibitor with an IC50 value of 36 nM. This imidazoquinazoline derivative effectively inhibits platelet aggregation and suppresses megakaryocyte development in the bone marrow. Additionally, Anagrelide hydrochloride has been shown to reduce the proliferation of gastrointestinal stromal tumor (GIST) cells and induce apoptosis in vitro, highlighting its potential as an antineoplastic agent. Its primary application lies in its role as a platelet-lowering agent with antithrombopoietic properties. -
ALDH Inhibitor/Local Anaesthetic
Dyclonine hydrochloride is a potent inhibitor of aldehyde dehydrogenases (ALDH), specifically targeting ALDH2 with an IC50 of 35 μM and ALDH3A1 with an IC50 of 76 μM. This compound exhibits notable biological activities, including the sensitization of targeted cancer cells and antibacterial properties. Additionally, Dyclonine hydrochloride serves as a local anesthetic, effectively inhibiting nerve impulse transmission and alleviating pain sensations. Its ability to cross the blood-brain barrier further enhances its utility in various research applications. -
IDH1-R132H Inhibitor
Alpha-Mangostin is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1-R132H), demonstrating a Ki of 2.85 μM. This dietary xanthone exhibits a diverse range of biological activities, including antioxidant, anti-inflammatory, antibacterial, and anticancer properties. It is valuable for research applications exploring metabolic pathways in cancer and the development of targeted therapies against IDH1-mutant tumors. -
Monoamine Oxidase Inhibitor
Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC50 value of 3 μM, making it a valuable tool in neuropharmacological research. In addition to its MAO inhibitory activity, isatin also interacts with central benzodiazepine receptors (IC50 against clonazepam, 123 μM) and acts as an antagonist of both atrial natriuretic peptide-stimulated and nitric oxide-stimulated guanylate cyclase activity. This compound's multiple mechanisms of action highlight its potential in studying the serotonergic system and its related pathways in various biological contexts. -
HMG-CoA Reductase Inhibitor
Pitavastatin is a potent HMG-CoA reductase inhibitor that effectively reduces cholesterol synthesis from acetic acid, demonstrating an IC50 of 5.8 nM in HepG2 cells. This compound functions as a potent inducer of low-density lipoprotein-cholesterol (LDL-C) receptors in hepatocytes. Additionally, Pitavastatin exhibits a broad range of biological activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects, making it valuable for research in cardiovascular health and metabolic disorders. -
CYP51 Inhibitor
CYP51-IN-30 is a potent inhibitor of CYP51, targeting sterol 14α-demethylase, an essential enzyme in sterol biosynthesis. This compound exhibits significant fungicidal activity, demonstrated by an EC50 value of 2.97 mg/L against Sclerotinia sclerotiorum. Its efficacy makes it a valuable tool for research in antifungal studies and applications in plant pathology. -
15-LOX Inhibitor
Asperenone is a potent inhibitor of 15-lipoxygenase (15-LOX), with an IC50 value of 0.3 mM, and effectively inhibits platelet aggregation at an IC50 of 0.23 mM. This compound also exhibits antifungal properties, demonstrating the ability to inhibit the growth of pathogenic fungi such as Ophiostoma crassivaginatum and O. piliferum. Asperenone is valuable for research in cardiovascular disease and antifungal therapy, providing a multifaceted approach to studying inflammatory processes and infection control. -
Succinate Dehydrogenase Inhibitor
SDH-IN-38 is a potent inhibitor of succinate dehydrogenase, primarily targeting mycelial respiration. Demonstrating significant antifungal activity, SDH-IN-38 exhibits an EC50 value of 0.009 μg/mL against R. solani mycelia, effectively inhibiting mycelial growth. Additionally, this compound induces cellular senescence and reduces mitochondrial membrane potential in fungal cells, making it a valuable tool for research in fungal biology and disease management.
